Products
ZORYVE® (roflumilast) topical foam, 0.3%
ZORYVE foam is a once-daily, steroid-free topical for seborrheic dermatitis and plaque psoriasis uniquely formulated for use anywhere on the body, including hair‑bearing areas.1
ZORYVE foam is the first drug approved with a new mechanism of action for seborrheic dermatitis in over two decades, and is now available for the treatment of plaque psoriasis.2 It’s bringing meaningful innovation to simplify disease management.1
About ZORYVE foam
ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
Important Safety Information
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
Please see the full Prescribing Information for ZORYVE foam below.
For more information,
visit the ZORYVE website.
Arcutis is dedicated to affordable access to therapy.
Our commitment to solving today’s biggest medical dermatology challenges doesn’t stop at bringing new treatment options. There’s more to our Arcutis DNA. It’s why we believe in responsible pricing and helping patients get access to our products through ZORYVE Direct and our commercial co-pay program, the ZORYVE Direct Savings Card Program, as well as Arcutis Cares.
ZORYVE Direct provides prescription status updates, refill reminders, and information to help patients stay on track with ZORYVE as prescribed by their healthcare provider. It also helps with out-of-pocket costs for eligible patients with commercial drug insurance.†
The Arcutis Cares patient assistance program (PAP) provides ZORYVE foam at no cost to eligible uninsured or underinsured patients with financial need.‡
†Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.
‡Subject to financial eligibility requirements. Other terms and restrictions apply.
References
- ZORYVE® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025.
- Data on File. Arcutis Biotherapeutics, Inc.
US-CRP-154-00015 05/25
Meaningful innovation at a glance.
Download our corporate fact sheet.
Download